Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
September 6, 2007

Aradigm and CyDex Combine Expertise to Tackle Asthma and COPD

  • Aradigm and CyDex are collaborating to combine products for the treatment of asthma and chronic obstructive pulmonary diseases (COPD).

    “Putting together Cydex’ aqueous formulation capabilities with Aradigm’s palm-size AERx Essence inhalation delivery system has the potential to generate a family of attractive novel therapies for asthma and COPD patients,” John Siebert, CEO of CyDex said.

    Under the two-year agreement, Aradigm will bear 60% of the costs of development, and CyDex will be responsible for the rest. Third-party licensing and sales revenues will be shared in the same ratio.

    The companies will develop and commercialize products containing inhaled corticosteroids, anticholinergics, and beta-2 agonists.

  • You’re all set! Thank you for subscribing to GEN Highlights.